KLP Kapitalforvaltning AS Invests $117,000 in uniQure N.V. $QURE

Key Points

• KLP Kapitalforvaltning AS has invested $117,000 in uniQure N.V. by purchasing 8,400 shares during the second quarter.
• Insider activity includes CEO Matthew C. Kapusta selling 226,316 shares for over $9.3 million, reducing his ownership by 25.78%.
• Analysts' price targets for uniQure vary significantly, with some increasing their targets up to $110, while maintaining a consensus rating of "Moderate Buy".

KLP Kapitalforvaltning AS purchased a new position in shares of uniQure N.V. (NASDAQ:QURE - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 8,400 shares of the biotechnology company's stock, valued at approximately $117,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mraz Amerine & Associates Inc. purchased a new stake in shares of uniQure in the 1st quarter valued at about $106,000. OMERS ADMINISTRATION Corp bought a new position in uniQure during the 1st quarter worth approximately $152,000. XTX Topco Ltd grew its position in shares of uniQure by 127.3% in the 1st quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company's stock worth $392,000 after buying an additional 20,720 shares during the last quarter. Rafferty Asset Management LLC bought a new stake in shares of uniQure in the 1st quarter worth approximately $875,000. Finally, Diamond Hill Capital Management Inc. lifted its stake in shares of uniQure by 22.8% in the 1st quarter. Diamond Hill Capital Management Inc. now owns 82,653 shares of the biotechnology company's stock valued at $876,000 after purchasing an additional 15,333 shares during the period. Hedge funds and other institutional investors own 78.83% of the company's stock.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 226,316 shares of the company's stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the sale, the chief executive officer directly owned 651,454 shares in the company, valued at $27,009,282.84. This represents a 25.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Christian Klemt sold 15,000 shares of the company's stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $55.00, for a total value of $825,000.00. Following the sale, the chief financial officer owned 217,730 shares in the company, valued at approximately $11,975,150. This trade represents a 6.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 244,316 shares of company stock worth $10,328,181. Company insiders own 4.79% of the company's stock.

uniQure Price Performance

NASDAQ:QURE opened at $63.07 on Wednesday. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The company has a market capitalization of $3.46 billion, a P/E ratio of -16.09 and a beta of 0.56. uniQure N.V. has a 12 month low of $5.35 and a 12 month high of $65.14. The business's 50-day moving average is $32.74 and its 200 day moving average is $20.40.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.20. The company had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. On average, equities research analysts forecast that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

QURE has been the subject of a number of recent research reports. Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, August 2nd. Chardan Capital lifted their price objective on uniQure from $35.00 to $76.00 and gave the stock a "buy" rating in a report on Thursday, September 25th. Guggenheim lifted their price objective on uniQure from $28.00 to $95.00 and gave the stock a "buy" rating in a report on Thursday, September 25th. HC Wainwright boosted their price target on uniQure from $70.00 to $110.00 and gave the company a "buy" rating in a report on Monday, October 6th. Finally, The Goldman Sachs Group upped their price objective on uniQure from $13.00 to $56.00 and gave the stock a "neutral" rating in a research note on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $71.75.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure N.V. (NASDAQ:QURE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.